Porownywarka
KPV vs Enfuvirtide side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | KPV | Enfuvirtide |
|---|---|---|
| Kategoria | Odporność | Odporność |
| Znany tez jako | Lys-Pro-Val, Alpha-MSH fragment | Fuzeon, T-20 |
| Zatwierdzony przez FDA | Nie | Tak |
| Status kliniczny | Preclinical research ongoing; no human clinical-trial benefit evidence was provided
| FDA approved; source also reports commercial discontinuation in February 2025 and withdrawal from US, UK, and Canadian markets.
|
| Czego oczekiwac | Gut inflammation, IBD, skin conditions and anti-inflammatory activity | HIV treatment, viral infection management |
| Jak dziala | KPV is described as a short alpha-MSH-derived peptide with a proposed anti-inflammatory mechanism. In the supplied evidence, KPV uptake is linked to PepT1 transport, particularly in inflamed intestinal tissue. After cellular entry, laboratory findings associate KPV with dampened NF-kB activity and reduced production of inflammatory mediators such as TNF-alpha, IL-1beta and IL-6. The source also states that KPV does not appear to act through the classic melanocortin receptors used by alpha-MSH, so the mechanism remains a preclinical working model rather than a confirmed clinical pathway. | Enfuvirtide is described as a peptide HIV fusion inhibitor that targets gp41. It resembles the HR2 segment of gp41 and binds the HR1 region, disrupting the conformational pairing needed to draw viral and host-cell membranes together. Because that fusion step is blocked, the virus is prevented from entering the cell through this pathway. |
| Typowe dawkowanie | 200-500 mcg daily · 1-2x daily | Limited community data available · See research protocols |
| Dawkowanie z badań | 200-500 mcg daily · 4-8 weeks typical · Subcutaneous injection or oral capsules | 90 mg subcutaneous twice daily · Twice daily · Ongoing as part of HIV regimen · Subcutaneous injection twice daily |
| Typowy czas trwania | 4-8 weeks typical | Ongoing as part of HIV regimen |
| Podanie | Subcutaneous injection or oral capsules | Subcutaneous injection twice daily |
| Timing | Morning, or as directed in the source context With or without food | Morning or as directed With or without food |
| Poziom dowodów | Przedkliniczne | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+4 więcej
|
+3 więcej
|
| Podsumowanie researchu | The supplied research summary places KPV in a preclinical evidence tier. It cites Dalmasso and colleagues in Gastroenterology in 2008 for PepT1-dependent uptake and reduced intestinal inflammation in experimental colitis models, including DSS and TNBS mouse models, alongside lower pro-inflammatory cytokine signals. A 2016 PMC-listed study is described as showing fewer tumors in a mouse model of colitis-associated cancer when KPV activity depended on PepT1. The source emphasizes that these are animal and in vitro findings and does not provide published randomized human trials for inflammatory bowel disease, eczema or other promoted uses. | The source characterizes enfuvirtide as a well-studied antiretroviral peptide rather than a speculative research compound. It cites the TORO 1 and TORO 2 phase 3 trials in heavily treatment-experienced participants, where enfuvirtide added to an optimized background regimen produced larger viral-load reductions than optimized background therapy alone. The source also notes earlier dose-ranging studies in HIV-infected adults, frequent injection-site reactions, practical burden from twice-daily injections, resistance linked to gp41 HR1 mutations, and combination-regimen use. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.